[Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
We report the case history of two female schizophrenic in-patients who exhibited a significant reduction of accompanying obsessive-compulsive symptoms under the combined treatment of neuroleptics and selective serotonin reuptake inhibitors (SSRIs). Our results indicate that the basic psychotic disorder was not exacerbated as a result of this additional treatment.
Scholl
H P
HP
Psychiatrische Universitätsklinik Bonn.
Kasper
S
S
Danos
P
P
Höflich
G
G
Möller
H J
HJ
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D010343:Patient Admission; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors
Selektive Serotonin-Wiederaufnahmehemmer in der Behandlung von Zwangssymptomen im Rahmen schizophrener Erkrankungen.